About EOS

Eos Neuroscience was founded in early 2007 to apply new innovations to the field of light-sensitive proteins to intractable neurological disease. This approach is now commonly referred to as optogenetics. Our first therapy is designed to restore functional sight to patients blind from photoreceptor diseases such as retinitis pigmentosa and macular degeneration. We achieved proof of concept in mice in 2008 and are now in preclinical development.

The Eos founding team consists of Dr. Ed Boyden, MIT professor and optogenetics pioneer; Dr. Alan Horsager, expert in visual neuroscience and therapeutic development who recognized the opportunity to dramatically improve outcomes with an optogenetic approach; and Ben Matteo, entrepreneur and former McKinsey consultant.

Eos is built on a collaboration-driven model.  Our worldwide core of experts has expertise covering basic research through clinical/regulatory.  The team has designed and managed clinical programs in gene therapy and the eye and has been involved in all aspects of primary research including transgenes, virology and gene expression, and retinal degeneration.  Eos is always looking for new collaborators and working on new applications.  Please contact us if you are interested in working with Eos.